Morten Rühwald

7.6k total citations · 1 hit paper
128 papers, 3.7k citations indexed

About

Morten Rühwald is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Morten Rühwald has authored 128 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Infectious Diseases, 89 papers in Epidemiology and 43 papers in Surgery. Recurrent topics in Morten Rühwald's work include Tuberculosis Research and Epidemiology (104 papers), Mycobacterium research and diagnosis (59 papers) and Diagnosis and treatment of tuberculosis (25 papers). Morten Rühwald is often cited by papers focused on Tuberculosis Research and Epidemiology (104 papers), Mycobacterium research and diagnosis (59 papers) and Diagnosis and treatment of tuberculosis (25 papers). Morten Rühwald collaborates with scholars based in Denmark, Switzerland and United States. Morten Rühwald's co-authors include Pernille Ravn, Jesper Eugen‐Olsen, Martine G. Aabye, Christoph Lange, Daniela María Cirillo, Morten Bjerregaard-Andersen, Delia Goletti, Peter Andersen, Jan Heyckendorf and Paulo Rabna and has published in prestigious journals such as The Lancet, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Morten Rühwald

116 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interferon-γ release assays for the diagnosis of latentMycobacterium tuberculosisinfection: a systematic review and meta-analysis

2010 403 citations Daniela María Cirillo, Christoph Lange et al. European Respiratory Journal profile →

Peers

Morten Rühwald

EPIDE

SURGE

IMMUN

Philippe Halfon France

Richard E. Nettles United States

Puneet Dewan India

Michael K. Mansour United States

Sandra M. Arend Netherlands

Alice Zwerling Canada

Kim Stanley South Africa

Jacqueline M. Achkar United States

Katalin A. Wilkinson United Kingdom

Philana Ling Lin United States

Philippe Halfon France

Morten Rühwald

2.4k ×0.8

4.7k ×2.0

EPIDE

475 ×0.3

SURGE

619 ×0.7

IMMUN

783 ×1.7

Citations per year, relative to Morten Rühwald Morten Rühwald (= 1×) peers Philippe Halfon

Countries citing papers authored by Morten Rühwald

Since Specialization

Citations

This map shows the geographic impact of Morten Rühwald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Morten Rühwald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Morten Rühwald more than expected).

Fields of papers citing papers by Morten Rühwald

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Morten Rühwald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Morten Rühwald. The network helps show where Morten Rühwald may publish in the future.

Co-authorship network of co-authors of Morten Rühwald

This figure shows the co-authorship network connecting the top 25 collaborators of Morten Rühwald. A scholar is included among the top collaborators of Morten Rühwald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Morten Rühwald. Morten Rühwald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abdulgader, Shima M., Arthur Chiwaya, Byron W P Reeve, et al.. (2025). Diagnostic accuracy of Truenat MTB Ultima on sputum for pulmonary tuberculosis diagnosis in an HIV-endemic setting. Clinical Microbiology and Infection. 31(7). 1203–1209. 1 indexed citations

Kohli, Mikashmi, Alexei Korobitsyn, Nazir Ismail, et al.. (2025). WHO target product profile for TB detection at peripheral settings: 2024 update. PLOS Global Public Health. 5(6). e0004612–e0004612.

Georghiou, Sophia B., Nestani Tukvadze, Camilla Rodrigues, et al.. (2025). Targeted next-generation sequencing for drug-resistant tuberculosis diagnosis: implementation considerations for bacterial load, regimen selection and diagnostic algorithm placement. BMJ Global Health. 10(11). e019135–e019135. 1 indexed citations

Bijker, Else M., Susan E. Dorman, Jerrold J. Ellner, et al.. (2024). One step further: improving paediatric TB diagnosis through user-centred research approaches. SHILAP Revista de lepidopterología. 1(9). 425–427.

Sebastián, J., Ioana D. Olaru, Matthew Arentz, et al.. (2024). Detection of other pathologies when utilising computer-assisted digital solutions for TB screening. SHILAP Revista de lepidopterología. 1(12). 533–539.

Crowder, Rebecca, Alfred Andama, Devasahayam Jesudas Christopher, et al.. (2024). Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein. Clinical Infectious Diseases. 82(2). e239–e247. 1 indexed citations

Gillespie, Stephen H., Andrew R. DiNardo, Sophia B. Georghiou, et al.. (2024). Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles. The Lancet Microbe. 5(9). 100869–100869. 3 indexed citations

Labhardt, Niklaus Daniel, Lucía González Fernández, Moniek Bresser, et al.. (2023). Head-to-head comparison of nasal and nasopharyngeal sampling using SARS-CoV-2 rapid antigen testing in Lesotho. PLoS ONE. 18(3). e0278653–e0278653. 2 indexed citations

MacLean, Emily, Paolo Miotto, Licé González-Angulo, et al.. (2023). Updating the WHO target product profile for next-generation Mycobacterium tuberculosis drug susceptibility testing at peripheral centres. SHILAP Revista de lepidopterología. 3(3). e0001754–e0001754. 18 indexed citations

10.

Hamada, Yohhei, Adam Penn‐Nicholson, Sriram Krishnan, et al.. (2022). Are mRNA based transcriptomic signatures ready for diagnosing tuberculosis in the clinic? - A review of evidence and the technological landscape. EBioMedicine. 82. 104174–104174. 21 indexed citations

11.

David, Anura, Margaretha de Vos, Lesley Scott, et al.. (2022). Feasibility, Ease-of-Use, and Operational Characteristics of World Health Organization–Recommended Moderate-Complexity Automated Nucleic Acid Amplification Tests for the Detection of Tuberculosis and Resistance to Rifampicin and Isoniazid. Journal of Molecular Diagnostics. 25(1). 46–56. 11 indexed citations

12.

Heyckendorf, Jan, Sophia B. Georghiou, Nicole Frahm, et al.. (2022). Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies. Clinical Microbiology Reviews. 35(3). 44 indexed citations

13.

Jenum, Synne, Kristian Tonby, Corina S. Rueegg, et al.. (2021). A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients. Nature Communications. 12(1). 6774–6774. 50 indexed citations

14.

Muyoyeta, Monde, Andrew D. Kerkhoff, Lophina Chilukutu, et al.. (2021). Diagnostic accuracy of a novel point-of-care urine lipoarabinomannan assay for the detection of tuberculosis among adult outpatients in Zambia: a prospective cross-sectional study. European Respiratory Journal. 58(5). 2003999–2003999. 11 indexed citations

15.

Georghiou, Sophia B., Riccardo Alagna, Daniela María Cirillo, et al.. (2021). Equivalence of the GeneXpert System and GeneXpert Omni System for tuberculosis and rifampicin resistance detection. PLoS ONE. 16(12). e0261442–e0261442. 4 indexed citations

16.

Vos, Margaretha de, Lesley Scott, Anura David, et al.. (2020). Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid. Journal of Clinical Microbiology. 59(3). 19 indexed citations

17.

Fröberg, Gabrielle, Margarida Correia‐Neves, Robert Szulkin, et al.. (2020). CD4+ T cell proliferative responses to PPD and CFP-10 associate with recent M. tuberculosis infection. Tuberculosis. 123. 101959–101959. 3 indexed citations

18.

Rühwald, Morten, et al.. (2019). IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting. Scientific Reports. 9(1). 3871–3871. 14 indexed citations

19.

Villar-Hernández, Raquel, Irene Latorre, María Luiza de Souza-Galvão, et al.. (2019). Use of IP-10 detection in dried plasma spots for latent tuberculosis infection diagnosis in contacts via mail. Scientific Reports. 9(1). 3943–3943. 5 indexed citations

20.

Ginsberg, Ann M., Morten Rühwald, Helen Mearns, & Helen McShane. (2016). TB vaccines in clinical development. Tuberculosis. 99. S16–S20. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact